FDA Inspection 1226038 — Tae Min Kim, M.D., Ph.D.
The FDA completed an inspection of Tae Min Kim, M.D., Ph.D. on December 15, 2023 in Seoul. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- December 15, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seoul (Korea (the Republic of))
Additional Details
Clinical Investigator (CI)